Clinical Trial News | Discover the new PCSK9-I

Exom starts an observational prospective multicenter study to assess the long-term effectiveness and tolerability of a new  PCSK9-I inhibitor in the real life clinical practice, in a severe hypercholesterolemic population resistant to full dosage statins. The study...

Exom Group launched Genius ENGAGE™

The first electronic Informed Consent fully combined with the eTMF Exom Group, the Human Digital CRO, has launched Genius ENGAGE™, the industry’s first ever electronic Informed Consent solution whose digital workflow is fully combined with the eTMF,  and integrated...

Exom Group Deploys Veeva Vault eTMF

For Efficient Document Management and Real-time Visibility Exom’s deployment of the eTMF has been selected by Veeva Inc. as a case study showing how the cloud-based Veeva Vault eTMF  streamlines trial processes and achieve greater efficiency. Veeva Vault eTMF is...